Sanofi in the news

The FDA approved Wayrilz, a new oral BTK inhibitor, for adults with chronic immune thrombocytopenia unresponsive to prior treatments, based on positive phase 3 trial results.

Wayrilz by Sanofi received US approval, and a ranking of most viewed stocks across major markets is provided.

Yves Jacob is named Head of R&D France at Sanofi, tasked with leading French research activities and collaborations while retaining his regulatory affairs role.

Sanofi's Wayrilz received FDA approval for treating adults with persistent or chronic immune thrombocytopenia unresponsive to prior therapies.

Sanofi expects a Q3 decline in vaccine sales due to a shift to Q4, while currency rates will positively impact revenue and EPS.

Sanofi expects a Q3 2026 dip in vaccine sales due to seasonality and competition, despite positive currency impacts.

Sanofi provided analysts with a Q3 2026 modelling guide to refine financial forecasts ahead of its October 30 earnings release, emphasizing transparency and its AI-enabled R&D portfolio.

Sanofi has made the aide-mémoire for its Q3 2026 results available on its investor page, with the full results to be published on October 30, 2026.

Sanofi expects a Q3 2026 vaccine sales decline due to seasonality and increased competition for its RSV immunization, despite positive currency impacts.

Sanofi shares experienced a 2.03% rebound to €71.41, yet remain significantly below their moving averages and are down 17.73% over the past year.

Sanofi anticipates a temporary Q3 decline in its Vaccines business due to a shifted influenza vaccination schedule, with sales deferred to Q4 2026.

Berenberg recommends buying Sanofi shares, maintaining a 105 EUR target price due to the stock's attractiveness.

Regeneron Pharmaceuticals expanded its antibody alliance with Sanofi with a $1 billion upfront payment and up to $7 billion in potential milestones, while also reporting new clinical data in oncology and obesity programs.

Sanofi transferred controlling stake of Opella to CD&R, securing French government commitments for local production and investments, while maintaining a significant financial interest in the company.

Sanofi's stock rose 1.4% to 71.80   after a previous fall, driven by recent collaborations with Regeneron and Cheplapharm, and share repurchases.

Sanofi's stock experienced a modest gain of 1.4% to •71.80, rebounding after a previous decline, driven by recent collaborations with Regeneron and Cheplapharm, and share repurchases.

Sanofi announced the publication of its "Q3 2026 aide-mémoire" document on its Investors page, ahead of its Q3 2026 results release on October 30, 2026.

Novavax shares surged 22% as Sanofi launched the Nuvaxovid COVID-19 vaccine for the fall season, utilizing Novavax's licensing business model.

Regeneron Pharmaceuticals expanded its antibody alliance with Sanofi for immunology treatments and reported new data for oncology and obesity therapies.